Australian company, Vaxine Pty Ltd, has developed a protein based COVID-19 vaccine that completely blocks virus transmission to non-immune individuals. The COVAX-19™ vaccine being developed by Australian company, Vaxine Pty Ltd, is set to be a game-changer in the fight against the COVID-19 pandemic and could allow earlier re-opening of national borders after it was shown to not only protect but also to completely block virus transmission to non-immune animals.
Vaxine’s biggest challenge now is to quickly raise the financial resources to complete Phase 3 human clinical trials and get Covid-19 vaccine manufactured at large scale which is likely to be in the order of $50 million dollars.
In another major breakthrough, Vaxine have also successfully created a breakthrough multivalent vaccine to protect against the new Covid-19 virus variants including the worrying South African, Brazilian and Indian mutant strains. The results of this multivalent Covid-19 vaccine formulation in animal testing is looking very promising.
Vaxine’s COVAX-19™ vaccine is a subunit vaccine based on synthetic protein produced using harmless insect cells to which Vaxine’s proprietary Advax polysaccharide adjuvant is added as a vaccine turbocharger to maximise the vaccine’s effectiveness and durability.
Vaxine is currently working with partners in overseas countries to assist in the upcoming phase 3 human clinical trials.
Vaxine has a long history of successfully developing pandemic vaccines, having previously developed vaccines against the SARS 3 and MERS coronaviruses that were shown to be highly protective in relevant animal models.
Global shipping costs have climbed to $4,000–$4,500 in October from $2,000–$2,500 in February 2026. Freight rates, which had eased through much of 2025 and early 2026 as the demand-supply balance improved, have rebounded sharply in recent months. The increase has brought shipping costs back into focus for businesses dependent on international cargo movement.
The U.S. Food and Drug Administration (FDA) has finalized guidance outlining how manufacturers should report post-approval manufacturing changes for biosimilar and interchangeable biosimilar products. The guidance provides greater regulatory clarity on changes involving production processes, manufacturing sites, analytical methods, raw materials, and process controls. It aims to ensure product quality while reducing unnecessary regulatory burden.
A significant uptick in M&A activity in the biosimilars sector is being driven by FDA regulatory reforms, a maturing patent litigation framework and a looming patent cliff — $200 billion of branded products are facing patent expiration by 2030.
The Drewry World Container Index edged lower this week as falling Asia-Europe rates outweighed firmer pricing on the Transpacific, with carriers preparing another round of blank sailings ahead of China’s Golden Week holiday.
On 14 July 2026, the European Parliamentary Research Service (EPRS) published a comprehensive briefing on PFAS (per- and polyfluoroalkyl substances), also known as ‘forever chemicals’. The document is intended to serve as a technical basis for MEPs in their upcoming political decisions on PFAS regulation and summarises the current state of scientific knowledge, regulation and procedures.
Following a series of typhoon disruptions in East China during the month of August, major ports including Shanghai and Ningbo continue to experience congestion and operational recovery challenges. Industry reports indicate that vessel schedules, yard operations, and equipment circulation remain affected as terminals work through accumulated backlogs from successive storm events.
Under REACH Annex XVII Entry 78, the EU has banned the placing on the market of synthetic polymer microparticles (SPMs) unless a specific derogation applies. Derogations exist for essential uses such as:
As a result of the amendment of the CLP Regulation (Regulation (EC) No 1272/2008 on the classification, labelling and packaging of substances and mixtures), new hazard classes have entered into force.
In a converging policy shift on both sides of the Atlantic, European regulators this week published a roadmap toward fully replacing animal testing for chemical safety assessments, while the US Environmental Protection Agency issued a rare update to its list of alternative test methods.